Evidence map›Paper›PMID 40710757›Full record

ReviewMembranes2025

A Mini Review of Reused End-of-Life Reverse Osmosis (EoL RO) Membranes.

Anissa Somrani, Kholoud Abohelal, Maxime Pontié

Abstract readReview
In one paragraph

Review in Membranes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anissa SomraniPhysics Department, College of Sciences, Jouf University, Sakaka P.O. Box 2014, Saudi Arabia.ORCID 0000-0003-0193-2830
Kholoud AbohelalPhysics Department, College of Sciences, Jouf University, Sakaka P.O. Box 2014, Saudi Arabia.
Maxime PontiéGroup of Analysis & Processes, Faculty of Sciences, University of Angers, CEDEX 01, 49045 Angers, France.ORCID 0000-0001-8751-3041

Funding

Jouf University This work was funded by the Deanship of Scientific Research at Jouf University in Saudi Arabia under Grant Number (DRS2022-RG-0140).
6 · The paper itself

Abstract

As sensitive parts of the water treatment process, reverse osmosis (RO) membranes are the most important for desalination and wastewater treatment. But the performance of RO membranes deteriorates over time due to fouling, necessitating frequent replacements. One of the environmental challenges is the disposal of End-of-Life (EoL) RO membranes, which are made of non-biodegradable polymers. The reuse of EoL membranes as a sustainable approach for waste saving and resource efficiency has recently attracted considerable attention. The present work provides a comprehensive overview of the strategies for reusing EoL RO membranes as sustainable alternatives to conventional disposal methods. Furthermore, the fundamental principles of RO technology, the primary types and impacts of membrane fouling, and advanced cleaning and regeneration techniques are discussed. The conversion of EoL membranes into nanofiltration (NF), ultrafiltration (UF), and forward osmosis (FO) membranes is also covered in this review, as well as their uses in brackish water desalination, dye/salt separation, groundwater treatment, and household wastewater reuse. Environmental and economic benefits, as well as technical, social, and regulatory challenges, are also discussed. Finally, the review highlights innovative approaches and future directions for incorporating EoL membrane reuse into circular economy models, outlining its potential to improve sustainability and reduce operational costs in water treatment systems.

Indexed as

circular economycleaning technologiesEoL RO membranesfoulingrecycling applications

Identifiers

PMID40710757
PMCPMC12300567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.